CCWM
CRBP icon

Cassaday & Co Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Cassaday & Co Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57 Sell
6
-6
-50% -$57 ﹤0.01% 1294
2026
Q1 		$113 Buy
+12
New +$101 ﹤0.01% 1321

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Cassaday & Co Wealth Management's CRBP Position: Q2 2026 in Review

Cassaday & Co Wealth Management reduced its Corbus Pharmaceuticals (CRBP) stake by 50% in Q2 2026, selling an estimated $57 and leaving 6 shares worth $57. The position accounts for ﹤0.01% of the portfolio, ranked #1294.

Cassaday & Co Wealth Management first reported a position in CRBP in Q1 2026 and has held it in 2 quarters since. The position peaked at $113 in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Cassaday & Co Wealth Management held 6 shares of Corbus Pharmaceuticals worth $57 as of Q2 2026.
  • Cassaday & Co Wealth Management sold 6 Corbus Pharmaceuticals shares in Q2 2026, an estimated $57.
  • Corbus Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1294 holding.
  • Cassaday & Co Wealth Management first reported a position in Corbus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Cassaday & Co Wealth Management's Corbus Pharmaceuticals position peaked at $113 in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.